Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–60.

Article  CAS  PubMed  Google Scholar 

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40(5):800–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3).

Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. 68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol. 2019;141:108–15.

Article  CAS  PubMed  Google Scholar 

Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, et al. Prediction of 177Lu-DOTATATE PRRT outcome using multimodality imaging in patients with gastroenteropancreatic neuroendocrine tumors: results from a prospective phase II LUMEN study. J Nucl Med. 2024;65(2):236–44.

Article  CAS  PubMed  Google Scholar 

Alipour R, Jackson P, Bressel M, Hogg A, Callahan J, Hicks RJ, et al. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable neuroendocrine neoplasms (NEN) treated with 177Lu DOTATATE (LuTate). Eur J Nucl Med Mol Imaging. 2023;50(10):2997–3010.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Syguła A, Ledwon A, Hasse-Lazar K, Jurecka-Lubieniecka B, Michalik B, Paliczka-Cieślik E, et al. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2022;49(11):3841–51.

Article  PubMed  Google Scholar 

Yordanova A, Wicharz MM, Mayer K, Brossart P, Gonzalez-Carmona MA, Strassburg CP, et al. The role of adding somatostatin analogues to peptide receptor radionuclide therapy as a combination and maintenance therapy. Clin Cancer Res. 2018;24(19):4672–9.

Article  CAS  PubMed  Google Scholar 

lutathera-epar-product. -information_en.pdf [Internet]. [cited 2024 Feb 27]. Available from: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf

Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K. MIRD pamphlet 26: joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151–62.

Article  CAS  PubMed  Google Scholar 

Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778–809.

Article  PubMed  PubMed Central  Google Scholar 

Dickson JC, Armstrong IS, Gabiña PM, Denis-Bacelar AM, Krizsan AK, Gear JM, et al. EANM practice guideline for quantitative SPECT-CT. Eur J Nucl Med Mol Imaging. 2023;50(4):980–95.

Article  PubMed  Google Scholar 

Chen EJ, Safwan Selvam HS, Tan TH, Chew MT. Quantitative analysis of xQuant reconstruction algorithm in SPECT/CT. Radiat Phys Chem. 2021;188:109683.

Article  CAS  Google Scholar 

Hoog C, Verrecchia-Ramos E, Dejust S, Lalire P, Sezin G, Moubtakir A, et al. Implementation of xSPECT, xSPECT bone and broadquant from literature, clinical survey and innovative Phantom study with task-based image quality assessment. Phys Med. 2023;112:102611.

Article  PubMed  Google Scholar 

Mahajan S, O’Donoghue J, Weber W, Bodei L. Integrating Early Rapid Post-peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting. J Nucl Med Radiat Ther [Internet]. 2019 [cited 2024 Jun 8];10(1). Available from: https://www.omicsonline.org/open-access/integrating-early-rapid-postpeptide-receptor-radionuclide-therapy-quality-assurance-scan-into-the-outpatient-setting-2155-9619-1000395-107659.html

Vergnaud L, Dewaraja YK, Giraudet AL, Badel JN, Sarrut D. A review of 177Lu dosimetry workflows: how to reduce the imaging workloads? EJNMMI Phys. 2024;11(1):65.

Article  PubMed  PubMed Central  Google Scholar 

Ha S, Kim YI, Oh JS, Yoo C, Ryoo BY, Ryu JS. Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour. EJNMMI Phys. 2024;11(1):14.

Article  PubMed  PubMed Central  Google Scholar 

Sanders JC, Kuwert T, Hornegger J, Ritt P. Quantitative SPECT/CT imaging of (177)Lu with in vivo validation in patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2015;17(4):585–93.

Article  CAS  PubMed  Google Scholar 

Huizing DMV, de Wit-van BJ, Verheij M, Stokkel MPM. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI Res. 2018;8:89.

Article  PubMed  PubMed Central  Google Scholar 

Tuncer O, Steinberger D, Steiner J, Hinojos M, Rhee SY, Humphrey B, et al. Quantitative SPECT/CT metrics in early prediction of [177 Lu]Lu-DOTATATE treatment response in gastroenteropancreatic neuroendocrine tumor patients. J Nucl Med. 2024;65(10):1584–90.

Article  CAS  PubMed  Google Scholar 

Calabrò D, Argalia G, Ambrosini V. Role of PET/CT and therapy management of pancreatic neuroendocrine tumors. Diagnostics (Basel). 2020;10(12):1059.

Article  PubMed  Google Scholar 

Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23(8):727–34.

Article  CAS  PubMed  Google Scholar 

Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906–14.

Article  PubMed  Google Scholar 

Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021;146:56–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–601.

Article  CAS  PubMed  Google Scholar 

Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society. Pancreas. 2017;46(6):715–31.

Article  PubMed  PubMed Central  Google Scholar 

Huizing DMV, Aalbersberg EA, Versleijen MWJ, Tesselaar MET, Walraven I, Lahaye MJ, et al. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. Cancer Imaging. 2020;20(1):57.

Article  PubMed  PubMed Central  Google Scholar 

Vinjamuri S, Gilbert TM, Banks M, McKane G, Maltby P, Poston G, et al. Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. Br J Cancer. 2013;108(7):1440–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]Octreotate: toxicity, efficacy, and survival. JCO. 2008;26(13):2124–30.

Article  CAS  Google Scholar 

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122–50.

Article  Google Scholar 

Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin Receptor–Mediated radionuclide therapy in patients with Well-Differentiated neuroendocrine tumors. J Nucl Med. 2010;51(9):1349–56.